Evidence map›Paper›PMID 42244249›Full record

ArticleCardiovascular therapeutics2026

Real-World Antithrombotic Management of Nonvalvular Atrial Fibrillation in Patients Undergoing Percutaneous Coronary Intervention in China: A Cross-Sectional Study.

Jiwei Yu, Shuolin Liu, Run Du, Qinglan Tao, Jinzhou Zhu, Fenghua Ding, Ruiyan Zhang, Zhengbin Zhu

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiwei YuDepartment of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn.ORCID https://orcid.org/0009-0009-3817-8836
Shuolin LiuDepartment of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn.ORCID https://orcid.org/0000-0002-7345-4172
Run DuDepartment of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn.ORCID https://orcid.org/0009-0003-6083-4146
Qinglan TaoDepartment of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn.ORCID https://orcid.org/0009-0002-5942-947X
Jinzhou ZhuDepartment of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn.ORCID https://orcid.org/0000-0002-2053-0135
Fenghua DingDepartment of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn.ORCID https://orcid.org/0000-0001-9507-4704
Ruiyan ZhangDepartment of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn.ORCID https://orcid.org/0000-0003-4131-8544
Zhengbin ZhuDepartment of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn.ORCID https://orcid.org/0000-0002-3068-7240

Funding

Science and Technology Commission of Shanghai Municipality 24SF1904800Science and Technology Commission of Shanghai Municipality 25SF1902203
6 · The paper itself

Abstract

Antithrombotic therapy in patients with nonvalvular atrial fibrillation (NVAF) undergoing percutaneous coronary intervention (PCI) is clinically challenging, with real-world strategies often remaining inconsistent. This study analyzed 2020 annual data from the Shanghai Cardiac Intervention Quality Control Center, encompassing 23,115 patients who underwent PCI across 36 centers in Shanghai. Among these, 1306 (5.65%) patients with a confirmed diagnosis of NVAF were enrolled. Dual antiplatelet therapy (DAPT) was the most common antithrombotic regimen (584, 44.7%). Anticoagulation therapy was administered to only 478 (55.8%) of male patients with a CHA

Indexed as

AnticoagulantsAtrial FibrillationCoronary Artery DiseaseFibrinolytic AgentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsStrokeAgedAged, 80 and overChinaCross-Sectional StudiesDual Anti-Platelet TherapyFemaleHumansMaleMiddle AgedAnticoagulantsFibrinolytic AgentsPlatelet Aggregation Inhibitorsanticoagulationantiplateletatrial fibrillationpercutaneous coronary intervention

Identifiers

PMID42244249
PMCPMC13238237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.